Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | NOX1 | Q9Y5S8 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL9853361 | 0.90 | GAA (0.41) | GAAMAPTMEN1KMT2ANOX1 | |
| Pivalate SCHEMBL9838291 | 0.86 | HSD17B10 (0.38) | GAAMAPTMEN1KMT2ANOX1 | |
| SCHEMBL10752613 | 0.80 | TYMS (0.41) | GAAMAPTMEN1KMT2ANOX1 | |
| SCHEMBL56711 | 0.79 | GAA (0.48) | GAAMAPTMEN1KMT2ANOX1 | |
| Phenothiazine SCHEMBL9809707 | 0.73 | NOX1 (0.71) | GAAMAPTMEN1KMT2ANOX1 | |
| SCHEMBL8874017 | 0.73 | GSK3B (0.56) | GAAMAPTMEN1KMT2ANOX1 | |
| SCHEMBL8874013 | 0.73 | GSK3B (0.56) | GAAMAPTMEN1KMT2ANOX1 | |
| SCHEMBL7376966 | 0.68 | MEN1 (0.42) | GAAMAPTMEN1KMT2ANOX1 | |
| SCHEMBL9460711 | 0.68 | NOX1 (0.61) | GAAMAPTMEN1KMT2ANOX1 | |
| Phenothiazine SCHEMBL11695283 | 0.67 | NOX1 (0.74) | GAAMAPTMEN1KMT2ANOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5120730-A | Vasodilation | IDB HOLDING SPA (IT) | 1992-06-09 | — | — | US | claimed |
| EP-0467537-A2 | Novel benzothiazepine esters, their preparation and formulations for therapeutic use | IDB HOLDING S.p.A. (IT) | 1992-01-22 | — | — | EP | claimed |
| US-5081240-A | PROCESS FOR THE PREPARATION OF BENZOTHIAZEPIN-ONE DERIVATIVES | SANOFI (FR) | 1992-01-14 | — | — | US | claimed |
| EP-0430012-A2 | Process for preparing 2-Aromatic-3-halobenzothiazepines | MARION MERRELL DOW INC. (US) | 1991-06-05 | — | — | EP | claimed |
| JP-6073034-A | — | — | None | — | — | JP | disclosed |
| JP-61130278-A | — | — | None | — | — | JP | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2025-05-29 | — | — | US | disclosed |
| US-20250049881-A1 | FORMULATIONS OF GUANYLATE CYCLSE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2025-02-13 | — | — | US | disclosed |
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2024-11-19 | — | — | US | disclosed |
| EP-4424697-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Bausch Health Ireland Limited (IE) | 2024-09-04 | — | — | EP | disclosed |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2024-08-29 | — | — | US | disclosed |
| EP-0381570-A1 | Process for the preparation of 1,5-benzothiazepin-4-one derivatives | ELF SANOFI (FR) | 1990-08-08 | — | — | EP | disclosed |
| EP-0381570-A1 | Process for the preparation of 1,5-benzothiazepin-4-one derivatives | ELF SANOFI (FR) | 1990-08-08 | — | — | EP | disclosed |
| EP-0292824-B1 | PROCESS FOR THE NUCLEAR CHLORINATION OF AROMATIC HYDROCARBONS | BAYER AG (DE) | 1990-08-01 | — | — | EP | disclosed |
| US-4851596-A | Process for nucleus-chlorination of aromatic hydrocarbons | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-25 | — | — | US | disclosed |
| EP-0292824-A1 | Process for the nuclear chlorination of aromatic hydrocarbons | BAYER AG (DE) | 1988-11-30 | — | — | EP | disclosed |
| JP-S61130278-A | 1,5-BENZOTHIAZEPIN-4(5H)-ONE DERIVATIVE AND PREPARATION THEREOF | HAMARI YAKUHIN KOGYO KK | 1986-06-18 | — | — | JP | disclosed |
| US-4547495-A | 1,5-Benzothiazepines with cardiovascular utility, and pharmaceutical compositions containing them | SCHIAPPARELLI FARMACEUTICI S.P.A. (IT) | 1985-10-15 | — | — | US | disclosed |
| US-4521430-A | VASODILATOR, ANTIISCHEMIC AGENT | TANABE SEIYAKU CO., LTD. (JP) | 1985-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | GAA 2064/4885MAPT 3318/4885MEN1 1006/4885 |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | GAA 2064/4885MAPT 3318/4885MEN1 1006/4885 |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | GAA 2064/4885MAPT 3318/4885MEN1 1006/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | GAA 2062/4885MAPT 4449/4885MEN1 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.